Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area
Discover our news
Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma
Boston Business Journal Names Servier Pharmaceuticals a Best Places to Work for the Fourth Consecutive Year
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D